Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ABVX

Abivax ADR

Sep 15 • 02:35PM ET

86.40

+2.39 2.84 %

Healthcare • Biotechnology • France • NASD

Peers: GILD VRTX AMGN REGN BIIB BMY MRNA PFE LLY NBIX

| Held by: PINK MMSC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.02	Insider Own	11.68%	Shs Outstand	75.57M	Perf Week	-4.00%
Market Cap	6.53B	Forward P/E	-	EPS next Y	-3.10	Insider Trans	0.00%	Shs Float	66.75M	Perf Month	24.21%
Enterprise Value	6.56B	PEG	-	EPS next Q	-0.73	Inst Own	30.78%	Short Float	2.43%	Perf Quarter	1137.82%
Income	-190.65M	P/S	-	EPS this Y	-5.62%	Inst Trans	37.58%	Short Ratio	1.03	Perf Half Y	1354.55%
Sales	0.00M	P/B	-	EPS next Y	6.37%	ROA	-66.45%	Short Interest	1.62M	Perf YTD	1080.33%
Book/sh	-0.89	P/C	91.27	EPS next 5Y	3.20%	ROE	-147.48%	52W High	92.91 -7.01%	Perf Year	635.32%
Cash/sh	0.95	P/FCF	-	EPS past 3/5Y	-1.20% -1.44%	ROIC	-	52W Low	4.77 1711.32%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.37% 4.23%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	18.47%	Oper. Margin	-	ATR (14)	3.95	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.77	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	71.01	Recom	1.15
Dividend Gr. 3/5Y	- -	Current Ratio	0.77	EPS Q/Q	-	SMA20	6.38%	Beta	0.73	Target Price	96.83
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	44.40%	Rel Volume	0.47	Prev Close	84.01
Employees	69	LT Debt/Eq	-	Earnings	Sep 08 AMC	SMA200	329.31%	Avg Volume	1.57M	Price	86.40
IPO	Oct 20, 2023	Option/Short	No / Yes	EPS/Sales Surpr.	3.99% -7.91%	Trades		Volume	585,583	Change	2.84%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-23-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$71
Mar-20-25	Initiated	Morgan Stanley	Equal-Weight	$12
Dec-04-24	Initiated	JMP Securities	Mkt Outperform	$33
Jul-29-24	Initiated	Laidlaw	Buy	$48
May-20-24	Initiated	BTIG Research	Buy	$43
Apr-29-24	Initiated	Piper Sandler	Overweight	$42
Apr-29-24	Initiated	Guggenheim	Buy	$50
Nov-14-23	Initiated	Morgan Stanley	Equal-Weight	$15
Nov-14-23	Initiated	Leerink Partners	Outperform	$20

Sep-12-25 11:45AM	Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review (GlobeNewswire)
Sep-08-25 04:00PM	Abivax Presents First Half 2025 Financial Results (GlobeNewswire)
Aug-30-25 05:30AM	How Hedge Funds Won Big on an Obscure Drugmaker (The Wall Street Journal)
Aug-01-25 06:46AM	Piper Sandler Raised the Firm's PT on ABIVAX Societe (ABVX), Kept an Overweight Rating (Insider Monkey)
Jul-31-25 11:31PM	Piper Sandler Raises Price Target for Abivax (ABVX) (Insider Monkey)
10:00AM	Loading…
10:00AM	This Stock Is Up by 800% This Year -- but Is It a Buy? (Motley Fool)
Jul-28-25 04:15PM	Abivax Announces Closing of $747.5 Million Public Offering (GlobeNewswire)
Jul-25-25 02:00AM	Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (637.5M) (GlobeNewswire)
Jul-24-25 04:02PM	Abivax (ABVX) Skyrockets 586% to New High on Promising Drug Trial, Bullish Analyst Outlooks (Insider Monkey)
08:40AM	Abivax announces trading resumption of its ordinary shares on Euronext Paris (GlobeNewswire)
08:40AM	Abivax Announces Pricing of $650M (554M) Public Offering of American Depositary Shares (GlobeNewswire)
01:30AM	Abivax announces temporary trading halt of its ordinary shares on Euronext Paris (GlobeNewswire)
Jul-23-25 04:15PM	Abivax Announces Launch of Public Offering (GlobeNewswire) +586.00%
04:11PM	Abivax Hits The Stratosphere, Up Nearly 600%, On 'Potentially Disruptive' Results (Investor's Business Daily)
Jul-22-25 04:05PM	Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis (GlobeNewswire)
04:00PM	Loading…
Jun-11-25 04:00PM	Abivax Announces Results of its June 6, 2025 Annual General Meeting (GlobeNewswire) -5.72% -5.39%
Jun-02-25 04:00PM	Abivax Presents First Quarter 2025 Financial Results (GlobeNewswire) +5.48% +21.89%
Apr-29-25 04:05PM	Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis (GlobeNewswire)
Apr-22-25 04:05PM	Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones (GlobeNewswire)
04:00PM	Abivax Announces Appointment of Dominik Hochli, MD to Board of Directors (GlobeNewswire)
04:00PM	Abivax Announces Appointment of Dominik H chli, MD to Board of Directors (GlobeNewswire)
Mar-27-25 07:20PM	ABIVAX: Undercovered, Late-Stage French Company With Upcoming Catalysts (SeekingAlpha) -5.72%
Mar-26-25 05:05PM	Abivax publishes financial reports with the French and U.S. securities regulatory agencies (GlobeNewswire)
Mar-24-25 03:30AM	Abivax Announces Full Year 2024 Financial Results (GlobeNewswire)
Feb-21-25 02:30AM	Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 (GlobeNewswire) +6.04%
Jan-28-25 02:30AM	Abivax Publishes 2025 Financial Calendar (GlobeNewswire)
Jan-23-25 04:05PM	Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress (GlobeNewswire)
Jan-09-25 11:35AM	Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment (GlobeNewswire)
Dec-23-24 04:05PM	Abivax Announces a Change to the Composition of its Board of Directors (GlobeNewswire)
Nov-19-24 04:30PM	Abivax Establishes an At-the-Market (ATM) Program on Nasdaq (GlobeNewswire)
04:01PM	Loading…
Nov-14-24 04:01PM	Abivax presents third quarter 2024 key financial information (GlobeNewswire)
Nov-13-24 04:01PM	Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax (GlobeNewswire)
Oct-07-24 04:01PM	Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation (GlobeNewswire)
Oct-03-24 04:01PM	Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease (GlobeNewswire)
02:31AM	Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance (GlobeNewswire)
Sep-26-24 02:30AM	Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 (GlobeNewswire)
Sep-25-24 04:01PM	Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model (GlobeNewswire)
Sep-09-24 04:01PM	Abivax presents first-half 2024 financial results (GlobeNewswire)
Aug-06-24 02:30AM	Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone (GlobeNewswire)
Jul-15-24 04:00PM	Abivax Provides Operational and Key Program Update (GlobeNewswire)
Jun-04-24 04:10PM	Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting (GlobeNewswire)
May-08-24 02:30AM	Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024 (GlobeNewswire)
May-07-24 04:00PM	Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents (GlobeNewswire)
Apr-05-24 04:00PM	Abivax publishes financial reports with the French and U.S. securities regulatory agencies (GlobeNewswire)
Apr-02-24 02:30AM	Abivax reports 2023 financial results and operational update (GlobeNewswire)
Feb-13-24 02:50AM	Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn's and Colitis Organization (ECCO) (ACCESSWIRE)
Feb-07-24 02:30AM	Abivax appoints Ana Sharma as Vice President, Global Head of Quality (GlobeNewswire)
Feb-02-24 02:30AM	Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn's disease (GlobeNewswire)
Jan-24-24 02:30AM	Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024 (GlobeNewswire)
Jan-22-24 02:30AM	Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months (GlobeNewswire)
Jan-04-24 02:30AM	Abivax 2024 Financial Communication Calendar (GlobeNewswire)
Nov-21-23 02:30AM	Abivax announces the resumption of its liquidity contract (GlobeNewswire)
Nov-14-23 08:00AM	Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Oct-24-23 04:15PM	Abivax Announces Closing of its Initial Public Offering on the Nasdaq Global Market (ACCESSWIRE) +7.90%

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABVX

Abivax ADR

Upgrade your FINVIZ experience